Danone has announced a series of investments to strengthen the local market capabilities, support and commitment of its Specialised Nutrition business in China. These investments will enable the company to broaden and deepen its range of nutritional products and services that are tailored to Chinese health needs, traditions and tastes.
Totalling around €100 million (US$113.9 million), these investments include the opening of an open-science research centre based in Shanghai, the acquisition of Murray Goulburm Dairy Qingdao from Saputo Dairy Australia, and the expansion of capacity to further develop offerings in food for special medical purposes (FSMP).
The new Danone Open Science Research Centre for Life-transforming Nutrition will serve as Danone’s platform to conduct studies and research in the region, focusing on breast milk and hut health. It will enable the company to develop more relevant nutrition products and services, building on local knowledge and science, and contributing to the country’s Healthy China 2030 agenda.
In coherence with its “One Planet. One Health” health frame of action, Danone also announced that its Early Life Nutrition business unit in the country has achieved B Corp certification. Danone added that the recognition positions the company as the biggest B Corp in Asia, which fully embodies the reality of its commitment towards the well-being of local populations and the preservation of local environment. It represents also an important step towards Danone’s accelerated ambition to become B Corp certified by 2025.
Véronique Penchienati-Bosetta, executive vice-president, specialised nutrition, Danone, said: “The opening of the Open Science Research Centre, the acquisition of local manufacturing capabilities and the B Corp certification are key milestones for Danone’s presence in China as they will allow us to further invest responsibly in the promotion of healthy and balanced diets, grounded in scientific research and tailored to Chinese nutritional and health needs, habits and traditions. This investment further demonstrates Danone’s belief in the long-term growth potential of the infant milk formula and medical nutrition market in China, and in the power of nutrition to positively impact health trajectories.”